Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health is supported by a highly defensible market position in a three-player U.S. pharmaceutical wholesaling oligopoly, with Pharma, specialty, and generics driving broad-based growth while FY27 adjusted EPS guidance rose to $12.80-$13.00. Its outlook is strengthened by vertical integration into higher-margin services, especially Other segment businesses such as Sonexus and nuclear medicine, which are expected to expand operating income through automation, CDMO capabilities, and specialty patient support. Even with customer-renewal timing, Solaris comparisons, and elevated petroleum costs moderating near-term Pharma growth, management’s stronger FY27 guidance and continued gains across all three Other businesses point to resilient earnings power and margin expansion.

Cardinal Health is facing a fundamentally challenged outlook because its core pharmaceutical distribution business operates in a highly competitive, razor-thin-margin industry where pricing pressure and input cost inflation can quickly erode profitability. The company’s growth levers also appear vulnerable: the generics tailwind is expected to taper over the next several years, specialty growth may not sustain its recent pace, and execution risks around the GMPD improvement plan, Sonexus expansion, and capital deployment could prevent margin expansion beyond the muted 1.8% downside assumption. In addition, regulatory and operational uncertainties around IRA drug pricing reform, nuclear approvals and compliance, and radioisotope supply could weigh on the 5-7% Pharma segment profit CAGR and the 15-17% profit CAGR targeted in the Other segment.